Avenzo Therapeutics Will Present Clinical Trial Data
The company will share Phase 1 results for its Nectin-4/TROP2 antibody-drug conjugate at the 2026 ESMO Asia Congress.
Updated on Oct. 14, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies are successfully advancing effective new cancer therapies?
Avenzo Therapeutics is scheduled to present preliminary Phase 1 clinical trial data for its investigational drug, VBC103, on December 4, 2026. The presentation will take place during the ESMO Asia Congress 2026 in Singapore.
Why it matters
As a potential first-in-class bispecific antibody-drug conjugate, VBC103 targets both Nectin-4 and TROP2 antigens to potentially help patients overcome resistance to previous cancer therapies.
The oral presentation, identified by abstract number 2370, is scheduled for 10:45-10:55 a.m. SGT. The study evaluates the investigational ADC, which uses a topoisomerase I inhibitor payload to target specific solid tumor antigens.
The players
Avenzo Therapeutics
A San Diego-based biotechnology company that holds the global development rights for AVZO-103 outside of Greater China.
Prof. Jian Zhang
The scheduled speaker who will present the clinical trial data during the upcoming congress.
VelaVigo
A pharmaceutical entity responsible for conducting the initial Phase 1 clinical study of the antibody-drug conjugate VBC103.
The details
Prof. Jian Zhang will present the data on VBC103, which is currently being developed as AVZO-103 by Avenzo Therapeutics for use outside of Greater China. The FDA has already granted Fast Track designation to the drug for locally advanced or metastatic urothelial cancer as clinical study of advanced solid tumors continues.
Timeline
The oral presentation of VBC103 clinical data is set for December 4, 2026.
The ESMO Asia Congress 2026 takes place from December 4 to December 6, 2026.
The Big Picture
The disclosure of findings at the ESMO Asia Congress highlights the ongoing focus on evaluating new oncology therapeutics within major medical forums. This presentation contributes to the broader evolution of antibody-drug conjugate research for advanced solid tumors.
This development may eventually offer new treatment pathways for patients with locally advanced or metastatic urothelial cancer. Current advancements in bispecific antibody-drug conjugates aim to provide alternative options for those who have developed resistance to existing therapies.
The takeaway
The upcoming presentation of Phase 1 data provides a critical early look at a potential first-in-class treatment molecule. Researchers and clinicians are closely monitoring such developments for their ability to broaden the utility of targeted antibody-drug conjugates.
Further reading
Find more updates on ongoing oncology research in the Cancer section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that pharmaceutical companies are successfully advancing effective new cancer therapies?
